Last $48.89 USD
Change Today +0.10 / 0.20%
Volume 64.1K
FMI On Other Exchanges
As of 2:23 PM 02/19/15 All times are local (Market data is delayed by at least 15 minutes).

foundation medicine inc (FMI) Snapshot

Previous Close
Day High
Day Low
52 Week High
01/12/15 - $54.28
52 Week Low
10/1/14 - $18.25
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

foundation medicine inc (FMI) Related Businessweek News

View More BusinessWeek News

foundation medicine inc (FMI) Details

Foundation Medicine, Inc. provides various molecular information products in the United States. Its molecular information platform generates actionable genomic information about a patient’s individual disease, enabling physicians to optimize treatments in clinical practice, and enabling biopharmaceutical companies to develop targeted oncology therapies. The company offers clinical products, such as FoundationOne for solid tumors; and FoundationOne Heme, for blood-based cancers, or hematologic malignancies, including leukemia, lymphoma, and myeloma, as well as sarcomas and pediatric cancers. It has strategic collaboration agreement with WuXi PharmaTech (Cayman) Inc. to provide genomic profiling to biopharmaceutical companies conducting clinical trials; and F. Hoffmann-La Roche Ltd. to enhance the identification and development of novel treatment options for cancer patients. The company was founded in 2009 and is headquartered in Cambridge, Massachusetts.

186 Employees
Last Reported Date: 03/7/14
Founded in 2009

foundation medicine inc (FMI) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $403.9K
Chief Operating Officer
Total Annual Compensation: $336.8K
Chief Medical Officer
Total Annual Compensation: $342.5K
Compensation as of Fiscal Year 2013.

foundation medicine inc (FMI) Key Developments

Foundation Medicine, Inc. Presents at Leerink's Global Healthcare Conference, Feb-11-2015 01:25 PM

Foundation Medicine, Inc. Presents at Leerink's Global Healthcare Conference, Feb-11-2015 01:25 PM. Venue: Waldorf Astoria New York, New York, New York, United States. Speakers: Steven Kafka, Chief Operating Officer.

F. Hoffmann-La Roche Ltd and Foundation Medicine, Inc. Enter into Strategic Collaboration to Develop New Cancer Treatments

F. Hoffmann-La Roche Ltd. and Foundation Medicine, Inc. entered into a strategic collaboration to enhance the identification and development of novel treatment options for cancer patients. Understanding the comprehensive genomic profile of a cancer patient's disease will enable better personalized healthcare solutions to optimize treatment outcomes for patients. Under the terms of the R&D collaboration agreement, Roche is committing to R&D funding of potentially more than $150 million for a minimum of five years and will contribute its expertise and breadth in oncology. FMI will continue to operate independently and will contribute its experience in the development of comprehensive genomic profiling tests for oncology. The initial focus of the R&D collaboration will be on developing genomic profile tests for cancer immunotherapies and for continuous blood-based monitoring. Roche will be able to utilize FMI's proprietary molecular information platform to standardize clinical trial testing. This aspect of the relationship is designed to enable comparability of clinical trial results for R&D purposes, and ultimately in the clinic. The R&D collaboration and FMI's current and future tests are expected to deliver insights to support development of combination therapies, novel targets, more accurate patient population identification and inclusion in clinical trials, and next generation companion diagnostics. In addition to the R&D collaboration, both parties also agreed to a commercial collaboration agreement designed to broaden FMI's position across clinical and molecular information markets. Specifically, Roche will obtain rights ex-US (under the FMI brand) to existing FMI products, as well as to future co-developed products. In the US, Roche will engage its US medical education team in providing medical information to pathologists.

Foundation Medicine, Inc. Launches New Version of Interactive Cancer Explorer

Foundation Medicine, Inc. has launched ICE 2, a new version of its Interactive Cancer Explorer, or ICE, physician portal. ICE 2 is designed to enable physicians to increase the efficiency of patient care utilizing Foundation Medicine tests and to enhance the utility of comprehensive genomic profiling. Among other updates, ICE 2 features PatientMatch - a feature that leverages Foundation Medicine's growing knowledgebase of more than 30,000 genomic profiles to help increase the actionability of FoundationOne and FoundationOne Heme results. Using PatientMatch, physicians within the Foundation Medicine network are able to connect with other physicians treating patients with similar genomic/tumor profiles to share treatment and outcomes information in a compliant manner. First launched in 2012, Foundation Medicine's online portal gives physicians access to test reports from FoundationOne and FoundationOne Heme on their tablet, computer or mobile device. ICE 2 offers several new features that increase the efficiency of patient care, including sample tracking, notifications and enhanced search, which allows physicians to find patients by gene, alteration or tumor type. In addition, ICE 2 features a brand new service called PatientMatch that identifies and connects physicians across Foundation Medicine's network who have seen patients with similar genomic profiles and tumor types, allowing them to share clinical experiences and outcomes data to help inform treatment decisions.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
FMI:US $48.89 USD +0.10

FMI Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Cancer Genetics Inc $8.80 USD +0.73
Genomic Health Inc $31.07 USD +0.05
NeoGenomics Inc $4.38 USD +0.09
Response Genetics Inc $0.54 USD -0.0214
Sequenom Inc $3.58 USD -0.065
View Industry Companies

Industry Analysis


Industry Average

Valuation FMI Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 26.3x
Price/Book 14.2x
Price/Cash Flow NM Not Meaningful
TEV/Sales 24.9x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact FOUNDATION MEDICINE INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at